Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 219.87B -37.6% |
| Revenue (ttm) | 42.26B +16.6% |
| Net Income | 13.89B +9.6% |
| EPS | 3.12 +10.1% |
| Shares Out | n/a |
| PE Ratio | 15.82 |
| Forward PE | 17.16 |
| Dividend | 1.56 (3.14%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 36 |
| Average Volume | 449,029 |
| Open | 48.84 |
| Previous Close | 50.20 |
| Day's Range | 48.02 - 49.39 |
| 52-Week Range | 35.76 - 90.46 |
| Beta | 0.36 |
| RSI | 50.62 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Obesity market sales potential tightens as Novo and Lilly enter new era
The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U.S. prices falling for GLP-1 treatments f...
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?
In December, it earned approval for the oral version of its famous medicine. Novo Nordisk's newest product launch is proving very popular.
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
Novo Nordisk obtained approval for its GLP-1 weight loss pill late last year. The company has already launched the drug, and there were more than 18,000 prescriptions in the U.S. in just its first wee...
5 Stocks Primed for a Turnaround in 2026
Everyone loves a good comeback story, and that's especially true in markets where business cycles ebb and flow. Last year's winners frequently turn into this year's laggards, and we've already seen ex...
Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
Novo Nordisk A/S has first-mover advantage in obesity pills and aggressive U.S. marketing, supported by a robust cash position, strengthen its competitive stance in the thriving GLP-1 market. Consensu...
New play in Denmark charts Novo Nordisk's weight loss boom
A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will premiere on Saturday at a theatre outside Copenhagen.
Novo's Wegovy pill tracks over 26,000 prescriptions
Novo Nordisk's Wegovy pill hits over 26,000 U.S. prescriptions in the second full week after its launch, IQVIA data shared by an analyst on Friday showed.
Novo Nordisk's China President Zhou to step down in March
Danish pharmaceutical company Novo Nordisk said on Friday that Senior Vice President and head of its business in China Christine Zhou will leave the company at the end of March.
2 Beaten-Down Growth Stocks Ready to Bounce Back
In this video, I will cover two beaten-down stocks that look ready to bounce back on any good news. Watch the short video to learn more, consider subscribing, and click the special offer link below.
Novo Nordisk: Investors May Be In For An Earnings Surprise
Novo Nordisk could be poised for a temporary negative sentiment swing as Q4 earnings may include highly conservative 2026 guidance despite strong oral Wegovy prescription momentum. Recent news - such ...
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines,...
1 Biotech Stock Set to Rebound in 2026
This weight-loss leader was drubbed last year. It's a popular pick as a 2026 rebound candidate.
1 Pharmaceutical Stock Set to Rebound in 2026
Novo Nordisk stock lost 40% of its value in 2025. The stock is already trading up 22% in 2026.
2 Pharmaceutical Stocks Set to Rebound in 2026
Novo Nordisk could see stronger financial results this year thanks to new launches and label expansions. Merck's clinical progress this year could show that it will expertly overcome a major upcoming ...
GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners
GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)
Novo Nordisk A/S's restructuring costs are front-loaded in Q3, with DKK 1 billion in savings accruing to Q4 earnings, setting up a potential beat on low expectations. The FDA-approved Wegovy oral pill...
Prediction: This Healthcare Stock Could Soar by 40% in 2026
Novo Nordisk had a rough stretch in 2025 that eventually led to it "firing" its CEO. The new Wegovy pill looks like a game-changer for the pharmaceutical giant.
Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog
Novo Nordisk was excessively punished by the market, trading at a significant discount to Eli Lilly despite robust fundamentals and global leadership in metabolic disease. NVO's global infrastructure,...
Novo Nordisk: This Run Is Just Getting Started
Novo Nordisk A/S stock has jumped 30% since my last coverage. NVO's first-mover advantage in oral GLP-1 positions it well despite rising competition and pricing pressures in obesity and diabetes marke...
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one...
Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch
Novo Nordisk's Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by an analyst on Friday showed.
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC spo...
Final Trade: SII, C, SMH, NVO
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Sesame Launches Wegovy® Pill Through Collaboration With Novo Nordisk
NEW YORK--(BUSINESS WIRE)--SESAME LAUNCHES WEGOVY® PILL THROUGH COLLABORATION WITH NOVO NORDISK.
Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026
Novo Nordisk A/S is poised for a turnaround in 2026, driven by renewed strategic focus under new CEO Maziar Doustdar. NVO's core strengths in diabetes and obesity, particularly with semaglutide, under...